US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aspire Biopharma Holdings Inc.

0.3805

+0.040511.91%

Post-market: 0.38100.0005+0.13%19:59 EDT

Volume:2.61M

Turnover:943.71K

Market Cap:18.84M

PE:-1.09

High:0.3880

Open:0.3348

Low:0.3300

Close:0.3400

Loading ...

Overview Company News Filings

Director Donald G. Fell Reports Acquisition of Common Shares in Aspire Biopharma Holdings Inc

Top Midday Gainers

MT Newswires Live

Aspire Biopharma to Launch Pre-Workout Supplement Buzz Bomb in Q3; Shares Jump

MT Newswires Live

Aspire Biopharma Initiates Phase 1 Trial for Fast-Acting High-Dose Aspirin Formulation, Aiming for Accelerated FDA Approval

Aspire Biopharma files to sell 8.33M shares of common stock for holders

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

ACCESS Newswire

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

ACCESS Newswire

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires Live

Aspire Biopharma Says Glatt Air Produces First Batch of Oral Mucosal Form of Aspirin

MT Newswires Live

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

ACCESS Newswire

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

ACCESS Newswire

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

ACCESS Newswire

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

ACCESS Newswire

BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics

PowerUp Acquisition Completes Combination; Aspire Biopharma Gains Nasdaq Listing

MT Newswires Live

Aspire Biopharma, PowerUp Acquisition complete business combination

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ASBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","market":"US","secType":"STK","nameCN":"Aspire Biopharma Holdings Inc.","latestPrice":0.3805,"timestamp":1749240000000,"preClose":0.34,"halted":0,"volume":2607601,"hourTrading":{"tag":"盘后","latestPrice":0.381,"preClose":0.3805,"latestTime":"19:59 EDT","volume":148954,"amount":55970.59848,"timestamp":1749254383629},"delay":0,"floatShares":35345600,"shares":49525970,"eps":-0.348055,"marketStatus":"Market Closed","change":0.0405,"latestTime":"06-06 16:00:00 EDT","open":0.3348,"high":0.388,"low":0.33,"amount":943705.8738337801,"amplitude":0.170588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.348055,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.34,"preHourTrading":{"tag":"盘前","latestPrice":0.3458,"preClose":0.34,"latestTime":"09:28 EDT","volume":45210,"amount":15530.530158,"timestamp":1749216510048},"postHourTrading":{"tag":"盘后","latestPrice":0.381,"preClose":0.3805,"latestTime":"19:59 EDT","volume":148954,"amount":55970.59848,"timestamp":1749254383629},"volumeRatio":0.830301631950549},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","floatShares":35345600,"roa":"-779.55%","roe":"--","lyrEps":-0.002976,"volumeRatio":0.830301631950549,"shares":49525970,"dividePrice":0,"high":0.388,"amplitude":0.170588,"preClose":0.34,"low":0.33,"week52Low":0.215,"pbRate":"-2.71","week52High":15.8,"institutionHeld":0,"latestPrice":0.3805,"eps":-0.348055,"divideRate":0,"volume":2607601,"delay":0,"ttmEps":-0.348055,"open":0.3348,"prevYearClose":11.5,"prevWeekClose":0.4301,"prevMonthClose":0.4301,"prevQuarterClose":0.5826,"fiveDayClose":0.4301,"twentyDayClose":0.3354,"sixtyDayClose":0.74},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541893062","title":"Director Donald G. Fell Reports Acquisition of Common Shares in Aspire Biopharma Holdings Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2541893062","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541893062?lang=en_us&edition=fundamental","pubTime":"2025-06-07 05:01","pubTimestamp":1749243686,"startTime":"0","endTime":"0","summary":"Donald G. Fell, a Director of Aspire Biopharma Holdings Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL3jdsbj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Donald G. Fell Reports Acquisition of Common Shares in Aspire Biopharma Holdings Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2539403168","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2539403168","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539403168?lang=en_us&edition=fundamental","pubTime":"2025-05-29 01:44","pubTimestamp":1748454295,"startTime":"0","endTime":"0","summary":"Spero Therapeutics (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4588","GSK","BK4608","BK4585","GSK.UK","BK4007","ASBP","SPRO","BK4023","SGN","LU1829250122.USD","BK4139"],"gpt_icon":0},{"id":"2538479472","title":"Aspire Biopharma to Launch Pre-Workout Supplement Buzz Bomb in Q3; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2538479472","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538479472?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:18","pubTimestamp":1748438337,"startTime":"0","endTime":"0","summary":"Aspire Biopharma  said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.The company has started initial production of the new supplement, which features 50mg of caffeine and is designed to support \"sustained energy and mental focus.\"Aspire Biopharma shares were 72% higher in premarket trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2536617618","title":"Aspire Biopharma Initiates Phase 1 Trial for Fast-Acting High-Dose Aspirin Formulation, Aiming for Accelerated FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2536617618","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536617618?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:32","pubTimestamp":1747744338,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc., headquartered in Humacao, Puerto Rico, has announced the dosing of the first patient in its Phase 1 clinical trial for an oral transmucosal fast-acting high-dose aspirin formulation. This trial is a single-center study conducted in the United States to evaluate the safety, pharmacokinetics, and pharmacodynamics of the company's lead therapeutic candidate. The trial involves healthy adult volunteers receiving a sublingual dose of 162.5 mg aspirin powder or granules, compared to control subjects given the same dose of oral aspirin. The primary outcome measure of the study will be plasma acetylsalicylic acid concentration over time. Aspire anticipates disclosing topline data from the trial early in the third quarter of 2025, which could potentially support accelerated approval, pending FDA review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL6B8n76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2535676033","title":"Aspire Biopharma files to sell 8.33M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2535676033","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535676033?lang=en_us&edition=fundamental","pubTime":"2025-05-14 05:30","pubTimestamp":1747171822,"startTime":"0","endTime":"0","summary":"17:26 EDT Aspire Biopharma (ASBP) files to sell 8.33M shares of common stock for holders Published first on TheFly – the ultimate source for real-t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-to-sell-8-33m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-to-sell-8-33m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2527549911","title":"Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream","url":"https://stock-news.laohu8.com/highlight/detail?id=2527549911","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527549911?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"MIAMI, April 15, 2025  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-81-110000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELRRF","BK4137","SBC","BK4135","BK4196","URG","USJW.SI","BK4139","NVA","NVIW.SI","CLNN","OMEX","BK4583","BK4168","PSQ","QLD","XXII","BK4075","HGRAF","ASBP","QID","BK4162","USEG","BIXT","NQmain","BK4124","UURAF","BNZI","NVA.AU","GOVX","BK4077","BK4023","SEVCF","TSYW.SI","BK4213","OPWEF","NVAWW","CIA","USAW.SI",".IXIC","CUAUF","BK4007","TQQQ","BK4584","MNQmain","BK4017","PSQH","BENF","SQQQ","EVFM"],"gpt_icon":1},{"id":"2526416661","title":"Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement","url":"https://stock-news.laohu8.com/highlight/detail?id=2526416661","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526416661?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:30","pubTimestamp":1744374600,"startTime":"0","endTime":"0","summary":"Plans to conduct consumer and safety testing during second quarter 2025. Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial production. Single dose pre-workout supplement expected to be available in at least three flavors and launch in specialty retailers of nutritional products in 2025. HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / April 11, 2025 / Aspire Biopharma Holdings, Inc.  , a developer of a multi-faceted patent-pending disruptive drug and supplement delivery technology, announced today it has begun initial production of its single dose pre workout supplement utilizing Aspire's patent-pending and proprietary sublingual delivery technology. The clinically dosed pre-workout formula is expected to be conveniently packaged in a single serving sachet for easy on-the-go use. The Company expects to begin consumer and safety testing of this supplement product during the second quarter of 2025.Aspire's initial pre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-commences-123000840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ASBP","ASBPW"],"gpt_icon":0},{"id":"2526336261","title":"Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2526336261","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526336261?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:30","pubTimestamp":1744201800,"startTime":"0","endTime":"0","summary":"Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product. Aspire anticipates releasing initial clinical data from trial at the end of the second quarter. Aspire intends to request \"fast track\" approval on FDA application for its high-dose aspirin product. HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc.  , a developer of a multi-faceted patent-pending drug delivery technology, today announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.Phase 1 Study DesignThe objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when administered orally in healthy adult volunteers. The Phase 1 clinical trial, which is being conducted in the United States, will compare the pharmacokinetic an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-announces-123000062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4104","BK4588","FAST","ASA","BK4007","BK4567","IE00B5TLWC47.USD","IE00BFXG0V08.USD","ASBPW","ASBP","IE00BYQQ9H92.USD","BK4585"],"gpt_icon":0},{"id":"2521646700","title":"Sector Update: Health Care Stocks Mixed in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2521646700","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521646700?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:02","pubTimestamp":1742493728,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed Thursday afternoon, with the NYSE Health Care Index rising 0.3% and the Health Care Select Sector SPDR Fund  fractionally lower.The iShares Biotechnology ETF  fell 1.1%.In corporate news, Aspire Biopharma  shares rose 2.3% after it said Thursday its contract manufacturer Glatt Air Techniques produced the first clinical batch of pharmaceutical-grade oral mucosal form of aspirin with Aspire's formulation ahead of a bioavailability study expected to begin in April.OptiNose  shares surged 52% after the company overnight said it agreed to be acquired by Paratek Pharmaceuticals in a deal valued at up to $330 million.Aptevo Therapeutics  shares added 1.1% after it said Thursday that two additional acute myeloid leukemia patients achieved remission within 30 days of treatment in a trial evaluating mipletamig with standard therapy for patients unfit for intensive chemotherapy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","IBB","OPTN","BK4588","BK4007","APVO","BK4139","ASBP","BK4585","BK4581"],"gpt_icon":1},{"id":"2520572794","title":"Aspire Biopharma Says Glatt Air Produces First Batch of Oral Mucosal Form of Aspirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2520572794","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520572794?lang=en_us&edition=fundamental","pubTime":"2025-03-20 22:10","pubTimestamp":1742479849,"startTime":"0","endTime":"0","summary":"Aspire Biopharma  said Thursday its contract manufacturer Glatt Air Techniques has produced the first clinical batch of pharmaceutical-grade oral mucosal form of aspirin with Aspire's formulation ahead of a bioavailability study expected to begin in April.The company said it is developing a high-dose sublingual aspirin in granular or powder form to allow fast absorption for cardiology emergencies and pain management.Aspire said it aims to complete chemistry, manufacturing and controls information for the product to support its submission to the US Food and Drug Administration. An initial meeting with the FDA is expected to be held in the second quarter, the company said.Price: 0.74, Change: +0.08, Percent Change: +11.76","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASBP","BK4007","AIRI","BK4187"],"gpt_icon":0},{"id":"2520456230","title":"Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2520456230","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520456230?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:30","pubTimestamp":1742473800,"startTime":"0","endTime":"0","summary":"Subsequent phase involves completion of chemistry, manufacturing, and controls  testing for data to support FDA submission. Company expects to commence bioavailability study in April 2025. Aspire intends to request \"fast track\" approval on FDA application for its high dose aspirin product. HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Aspire Biopharma Holdings, Inc.  , a developer of a multi-faceted patent pending drug delivery technology, today announced that it its contract manufacturer, Glatt Air Techniques, Inc., part of Glatt Group, a vertically integrated pharmaceutical services company with FDA- and EU-approved sites, has completed its first Good Manufacturing Practice  Clinical Batch of its pharmaceutical-grade oral mucosal formulation of aspirin that utilizes Aspire's fast-acting formulation. Aspire's GMP extracts are set to be administered in a bioavailability study in healthy human volunteers in April 2025.Following release of the GMP Clinical Batch by Gl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-contract-123000458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1363072403.SGD","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","CMC","IE00BHPRN162.USD","LU0149725797.USD","BK4007","BK4585","LU0267386448.USD","IE00BZ1G4Q59.USD","IE00B5TLWC47.USD","BK4588","BK4567","IE00B1BXHZ80.USD","FAST","BK4104","ASBPW","LU0971096721.USD","IE00BKVL7J92.USD","LU0170899867.USD","BK4006","ASBP","LU0882574139.USD"],"gpt_icon":0},{"id":"2519839355","title":"Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2519839355","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519839355?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:30","pubTimestamp":1741869000,"startTime":"0","endTime":"0","summary":"A provisional patent application is a critical step on the road to commercial viability. As the climate for intellectual property rights becomes increasingly competitive, a provisional patent application establishes an early effective filing date for any subject matter disclosed in the provisional application and allows the patent applicant or a licensee to ascribe the phrase \"patent pending\" to any product or method covered by the provisional application.The Company believes its patent pending technology is groundbreaking because it offers significant advantages over existing oral formulations of numerous prescription and non-prescription products due to its new mechanism of action  which allows for rapid sublingual absorption. The benefits of \"rapid absorption\" are to provide nearly instant treatment impact and high dose absorption. The Company's patent pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs into the blood str","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-provides-123000855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASBP","ASBPW","BK4007"],"gpt_icon":1},{"id":"2518434107","title":"An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2518434107","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518434107?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"SmallCaps Daily Dives Deep with CEO Kraig Higginson to Discuss Aspire's Mission to Enhance Efficacy and Reduce Side Effects. New York, New York-- - Aspire Biopharma Holdings, Inc.   is revolutionizing drug delivery through its proprietary sublingual technology, designed to rapidly deliver therapeutics while bypassing the gastrointestinal tract and liver. SmallCaps Daily sat down with CEO Kraig Higginson to learn more about Aspire's mission to enhance existing drugs-from fast-acting aspirin and ED treatments to hormonal therapies and supplements-while reducing side effects and improving patient outcomes. With multiple product launches expected this year and a focus on strategic licensing partnerships with major pharmaceutical players, Aspire Biopharma is positioning itself at the forefront of a $100 billion industry primed for innovation.About Aspire Biopharma, Inc.Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/interview-ceo-aspire-biopharma-disrupting-120000914.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/interview-ceo-aspire-biopharma-disrupting-120000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ASBPW","ASBP"],"gpt_icon":0},{"id":"2516956638","title":"Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516956638","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516956638?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:30","pubTimestamp":1741005000,"startTime":"0","endTime":"0","summary":"New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout market. Desert Stream Inc., a well-established nutritional and supplement manufacturer of caffeine-based products, engaged for sourcing of ingredients, lab studies, regulatory compliance, and quality control.\"We are excited about the opportunity to leverage our delivery technology into the very large and growing pre-workout supplement market,\" commented Kraig Higginson, Chief Executive Officer of Aspire. \"Many caffeine-based pre-workout products are delivered in liquid formulations and typically consumed thirty minutes before a person begins their fitness program. Much of the caffeine is synthesized in the digestive process and liver, potentially delaying the peak performance boost an athlete or fitness enthusiast is seeking. Utilizing our science-backed approach, Aspire has developed a pre-workout product that uses our subling","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-launch-123000813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASBP","ASBPW"],"gpt_icon":0},{"id":"2514096763","title":"Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096763","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096763?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:30","pubTimestamp":1740486600,"startTime":"0","endTime":"0","summary":"Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete. Test results support the next development step with Phase 1clinical trial expected to commence in April. Aspire's lead product candidate, high-dose sublingual aspirin, is a granular or powder formulation of a soluble, Ph neutral, fast-acting aspirin designed to address cardiology emergencies and pain management. Aspire believes the benefits of \"rapid absorption\" aspirin include the potential to quickly stop heart attack and stroke; allow high dose absorption for pain management including fast headache relief, post-surgery, cancer pain management, and general pain relief.\"Today's announcement represents a significant milestone for Aspire, and we believe the speed and level of absorption due to our new mechanism of action into the blood stream is significant and represents a new disruptive drug delivery technology,\" commented Kraig Higginson, Chief Executive Officer of A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aspire-biopharma-holdings-inc-provides-123000612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASBP","ASBPW"],"gpt_icon":0},{"id":"2513821832","title":"BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2513821832","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513821832?lang=en_us&edition=fundamental","pubTime":"2025-02-22 01:18","pubTimestamp":1740158328,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Mo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3N3PC1FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237957811.SGD","GLOB","SEM","BLUE","89618","GKOS","ODFL","RL","CON","ATMU","ED","MELI","RIVN","FND","LU0588545490.SGD","SEI","AMAL","CRWD","UPC","WST","RLX","WAY","LU0496365809.HKD","CMCM","MNDR","SLRN","FSUN","PTGX","ACCO","UNH","BKNG","COIN","LU2272731782.SGD","AKAM","MGTX","HBCP","ASBP","BK4023","CELH"],"gpt_icon":1},{"id":"2512331774","title":"PowerUp Acquisition Completes Combination; Aspire Biopharma Gains Nasdaq Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2512331774","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512331774?lang=en_us&edition=fundamental","pubTime":"2025-02-20 02:50","pubTimestamp":1739991036,"startTime":"0","endTime":"0","summary":"PowerUp Acquisition  completed a business combination with Aspire Biopharma, which will debut on the Nasdaq on Thursday.Aspire shares will trade under the ticker ASBP with the options symbol of ASBPW.The business combination is expected to provide improved access to sources of new capital and expand the internal development of new product offerings, among other things, Aspire and PowerUp, a blank-check company, said Wednesday in a statement.Aspire, based in Humacao, Puerto Rico, develops drug delivery technology.Price: 9.24, Change: -0.04, Percent Change: -0.43","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2210149790.SGD","USAW.SI","LU2210150020.SGD","NDAQ","BK4585","NVIW.SI","NQmain","ASBP","IE00BKPKM429.USD","LU2095319765.USD","PWUP","MNQmain","USJW.SI","BK4112","IE00BGHQF748.EUR","PSQ","QLD","BK4588","QID","IE00B3QW5Z07.USD","TQQQ","SQQQ","TSYW.SI",".IXIC","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2512357433","title":"Aspire Biopharma, PowerUp Acquisition complete business combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2512357433","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512357433?lang=en_us&edition=fundamental","pubTime":"2025-02-20 02:20","pubTimestamp":1739989217,"startTime":"0","endTime":"0","summary":"Aspire Biopharma (ASBP), a developer of a drug delivery mechanism technology, and PowerUp Acquisition Corp. (PWUP), a Nasdaq Global Market listed s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-powerup-acquisition-complete-business-combination?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-powerup-acquisition-complete-business-combination?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASBP","PWUP","TSYW.SI","USAW.SI","MNQmain","QID",".IXIC","SQQQ","USJW.SI","NVIW.SI","PSQ","QLD","NQmain","TQQQ"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASBP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASBP","date":"2025-06-06","current":-0.976857,"percent":0.895522,"low":-107.647863,"twenty":-45.929755,"median":-36.514155,"eighty":-4.677726,"high":-0.643502,"avg":-32.533401,"sd":20.983312,"marketCap":16626329},"quantilePoints":[{"date":"2025-03-07","current":-61.718107,"twenty":-79.515888,"median":-61.718107,"eighty":-58.474317,"marketCap":40003023},{"date":"2025-03-14","current":-41.62384,"twenty":-63.871064,"median":-57.344015,"eighty":-54.828644,"marketCap":26978783},{"date":"2025-03-21","current":-49.388839,"twenty":-61.718107,"median":-55.259235,"eighty":-45.464716,"marketCap":32011722},{"date":"2025-03-28","current":-47.36506,"twenty":-59.766092,"median":-48.376949,"eighty":-45.613987,"marketCap":30699995},{"date":"2025-04-04","current":-38.75323,"twenty":-56.183571,"median":-46.367595,"eighty":-43.647619,"marketCap":25118177},{"date":"2025-04-11","current":-38.035578,"twenty":-55.34679,"median":-45.929755,"eighty":-40.946376,"marketCap":24653026},{"date":"2025-04-17","current":-39.57853,"twenty":-55.287942,"median":-45.474044,"eighty":-39.546954,"marketCap":25653101},{"date":"2025-04-25","current":-36.428037,"twenty":-53.967461,"median":-44.487272,"eighty":-38.006872,"marketCap":23611087},{"date":"2025-05-02","current":-25.763721,"twenty":-50.875815,"median":-42.879731,"eighty":-36.06634,"marketCap":16698936},{"date":"2025-05-09","current":-24.070062,"twenty":-48.174572,"median":-41.62384,"eighty":-32.456117,"marketCap":15601179},{"date":"2025-05-16","current":-8.64997,"twenty":-47.360753,"median":-40.170558,"eighty":-27.896584,"marketCap":11330354},{"date":"2025-05-23","current":-0.643502,"twenty":-46.76371,"median":-38.75323,"eighty":-25.110657,"marketCap":10952545},{"date":"2025-05-30","current":-1.730761,"twenty":-46.192459,"median":-37.963813,"eighty":-23.557658,"marketCap":29457944},{"date":"2025-06-06","current":-0.976857,"twenty":-45.929755,"median":-36.514155,"eighty":-4.677726,"marketCap":16626329}],"updateTime":1749327018140}}}